P. Ott

Personalized neoantigen-targeting cancer vaccines in ovarian cancer: a phase 1 trial.

The interplay between the repertoire of antigens presented by the tumor and the breadth of induced immunity seemed to dictate clinical efficacy following vaccination, and this was associated with broader tumor and vaccine-specific immune responses in blood and tumor following vaccination.

72 Time-of-day of Immune Checkpoint Inhibitor Infusion and Overall Survival in Renal Cell Carcinoma: A Real-World Cohort Analysis

Abstract Background Previous retrospective work found an association between earlier immune-checkpoint inhibitors (ICI) infusion times and survival outcomes in renal cell carcinoma (RCC). A recent randomized trial in non-small cell lung cancer (NSCLC) also reported benefit, however, a recent analysis of several randomi...

Programmable antigen-presenting scaffolds expand rare tumor-antigen-specific T cells from peripheral blood

Tertiary lymphoid structures harbour stem-like tumour-specific T cells

Tertiary lymphoid structures are reservoirs of tumour-specific T cells with stem-like progenitor features that could be leveraged by T cell immunotherapies, and are found to be reservoirs of tumour-specific T cells with stem-like progenitor features that could be leveraged by T cell immune pressure.